Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022

Rhea-AI Summary

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 2:50 p.m. Eastern Time. The conference is virtual, and a live webcast will be available on Acadia’s website, with an archived recording accessible until April 9, 2022.

Acadia focuses on breakthroughs in neuroscience, notably developing the first approved therapy for hallucinations and delusions related to Parkinson’s disease psychosis and is targeting psychosis in dementia, schizophrenia, and Rett syndrome.

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Cowen 42^nd Annual Health Care Conference on Wednesday, March 9, 2022 at 2:50 p.m. Eastern Time.

The conference will be held virtually. A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through April 9, 2022.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on treating psychosis in patients with dementia, the negative symptoms of schizophrenia and Rett syndrome. Our early-stage development efforts are focused on novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220303005324/en/

Media Contact:

Acadia Pharmaceuticals Inc.

Deb Kazenelson

(818) 395-3043

media@acadia-pharm.com

Investor Contact:

Acadia Pharmaceuticals Inc.

Mark Johnson, CFA

(858) 261-2771

ir@acadia-pharm.com

 

Source: Acadia Pharmaceuticals Inc.

FAQ

When will Acadia Pharmaceuticals present at the Cowen Health Care Conference?

Acadia Pharmaceuticals will present on March 9, 2022, at 2:50 p.m. Eastern Time.

How can I access the Acadia Pharmaceuticals conference presentation?

The presentation can be accessed via a live webcast on Acadia's website.

What is the focus of Acadia Pharmaceuticals' development efforts?

Acadia Pharmaceuticals is focused on developing treatments for psychosis in dementia, schizophrenia, and pain management in central nervous system disorders.

What is the ticker symbol for Acadia Pharmaceuticals?

The ticker symbol for Acadia Pharmaceuticals is ACAD.

Until when will the Acadia Pharmaceuticals presentation be available for replay?

The archived recording of the presentation will be available until April 9, 2022.